Side-by-side · Research reference
DSIPvsHexarelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/36 cited
BPhase 1Reviewed19/45 cited
DSIP
Sleep modulator · Anti-stress
SQ · Pre-sleep · Daily during cycle
Hexarelin
Hexapeptide GHRP · Cardio-tropic
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
DSIP
Hexarelin
Primary target
Multiple — modulates HPA axis + thalamic delta-wave generation (proposed)Schneider 1986
Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996Ghigo 1997
Pathway
Reduced cortisol/ACTH + enhanced delta-wave EEG activity → improved sleep onset + depthSchneider 1986
GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997
Downstream effect
Faster sleep onset, increased delta sleep, reduced stress response, possible anxiolytic effectSchneider 1986
Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997
Origin
Endogenous peptide first isolated from rabbit blood during delta sleep; synthesised exogenouslySchneider 1986
Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996
Antibody development
—
—
02Dosage Protocols
Parameter
DSIP
Hexarelin
Frequency
Once daily, pre-sleep
1–2× per day max (tachyphylaxis with chronic 3× daily)
Lower / starter dose
50 mcg pre-sleep
50 mcg per dose
Evidence basis
Human-mechanistic + early clinicalSchneider 1986
Phase 1 / Phase 2 trialsSmith 1996Ghigo 1997
Duration
8–12 weeks per cycle
4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)
Reconstitution
Bacteriostatic water
Bacteriostatic water
Timing
30–60 min pre-sleep
Pre-sleep + fasted preferred
04Side Effects & Safety
Parameter
DSIP
Hexarelin
Injection site reaction
Mild irritation
—
Drowsiness
Expected effect (intentional)
—
Vivid dreams
Anecdotally reported
—
Long-term safety
Limited modern RCT data
—
Pregnancy / OB
Avoid
Avoid
Hunger
—
Strong appetite increase via ghrelin agonism
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Absolute Contraindications
DSIP
- ·Pregnancy / breastfeeding
- ·Concurrent CNS-depressant therapy without supervision
Hexarelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
DSIP
- ·Severe sleep apnoea (untreated)
- ·Concurrent benzodiazepine / opioid use
Hexarelin
- ·Untreated diabetes
- ·Severe hyperprolactinemia
05Administration Protocol
Parameter
DSIP
Hexarelin
1. Reconstitution
Add 1–2 mL bacteriostatic water to vial.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Injection site
SQ — abdomen. Rotate sites.
SQ — abdomen or thigh. Rotate sites.
3. Timing
30–60 min pre-sleep.
Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
29–31G insulin syringe.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
DSIP
— no documented stacks
Hexarelin
+ CJC-1295 (no DAC)
StrongHexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.
- Hexarelin
- 100 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- Maximum GH pulse amplitude (with side-effect signal)